Align Technology, Inc. (ALGN) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $158.60 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 2.8): -1.5; Concentration risk — Product: Clear Aligner (80.0%).
Align Technology develops and markets the Invisalign clear aligner system, iTero intraoral scanners, and exocad CAD/CAM software for orthodontic and dental practices globally, with Clear Aligner representing ~80% of worldwide net revenues. Revenue is driven by doctor-prescribed... Read more
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $158.60 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 2.8): -1.5; Concentration risk — Product: Clear Aligner (80.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.5/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Align Technology, Inc.
Latest news
- Align Technology (ALGN) Moves Forward with $200 Million Stock Bu - GuruFocus — GuruFocus positive
- Align Technology (ALGN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance neutral
- (ALGN) Align Technology, Inc. Expects Q2 Revenue Range $1.04B - $1.06B - marketscreener.com — marketscreener.com positive
- Earnings Flash (ALGN) Align Technology, Inc. Posts Q1 Adjusted EPS $2.58 per Share, vs. FactSet Est of $2.30 - marketscr — marketscreener.com positive
- Align Technology (NASDAQ:ALGN) Surprises With Q1 CY2026 Sales - StockStory — StockStory positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductClear Aligner80%10-K Item 1: 'Clear Aligner net revenues represented approximately 80% of worldwide net revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $158.60 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 2.8): -1.5; Concentration risk — Product: Clear Aligner (80.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $151.22. Score 5.5/10, moderate confidence.
Take-profit target: $181.89 (+14.6% upside). Prior stop was $151.22. Stop-loss: $151.22.
Concentration risk — Product: Clear Aligner (80.0%); Leverage penalty (D/E 2.8): -1.5; Consecutive earnings misses (2).
Align Technology, Inc. trades at a P/E of 26.7 (forward 12.8). TrendMatrix value score: 7.0/10. Verdict: Sell.
24 analysts cover ALGN with a consensus score of 4.0/5. Average price target: $209.
What does Align Technology, Inc. do?Align Technology develops and markets the Invisalign clear aligner system, iTero intraoral scanners, and exocad CAD/CAM...
Align Technology develops and markets the Invisalign clear aligner system, iTero intraoral scanners, and exocad CAD/CAM software for orthodontic and dental practices globally, with Clear Aligner representing ~80% of worldwide net revenues. Revenue is driven by doctor-prescribed Invisalign treatments sold to orthodontists and general practitioners, with over 22 million patients treated to date.